Association of Systolic Blood Pressure with Macrovascular and Microvascular Complications of Type 2 Diabetes (UKPDS 36): Prospective Observational Study

Overview

Journal BMJ

Specialty General Medicine

Date 2000 Aug 11

PMID 10938049

Citations 523

Authors

A I Adler

I M Stratton

H A Neil

J S Yudkin

D R Matthews

C A Cull

A D Wright

R C Turner

R R Holman

Affiliations

Soon will be listed here.

Abstract

Objective: To determine the relation between systolic blood pressure over time and the risk of macrovascular or microvascular complications in patients with type 2 diabetes.

Design: Prospective observational study.

Setting: 23 hospital based clinics in England, Scotland, and Northern Ireland.

Participants: 4801 white, Asian Indian, and Afro-Caribbean UKPDS patients, whether randomised or not to treatment, were included in analyses of incidence; of these, 3642 were included in analyses of relative risk.

Outcome Measures: Primary predefined aggregate clinical outcomes: any complications or deaths related to diabetes and all cause mortality. Secondary aggregate outcomes: myocardial infarction, stroke, lower extremity amputation (including death from peripheral vascular disease), and microvascular disease (predominantly retinal photocoagulation). Single end points: non-fatal heart failure and cataract extraction. Risk reduction associated with a 10 mm Hg decrease in updated mean systolic blood pressure adjusted for specific confounders.

Results: The incidence of clinical complications was significantly associated with systolic blood pressure, except for cataract extraction. Each 10 mm Hg decrease in updated mean systolic blood pressure was associated with reductions in risk of 12% for any complication related to diabetes (95% confidence interval 10% to 14%, P<0.0001), 15% for deaths related to diabetes (12% to 18%, P<0.0001), 11% for myocardial infarction (7% to 14%, P<0.0001), and 13% for microvascular complications (10% to 16%, P<0.0001). No threshold of risk was observed for any end point.

Conclusions: In patients with type 2 diabetes the risk of diabetic complications was strongly associated with raised blood pressure. Any reduction in blood pressure is likely to reduce the risk of complications, with the lowest risk being in those with systolic blood pressure less than 120 mm Hg.

Citing Articles

Association between obstructive sleep apnea hypopnea syndrome and arteriosclerosis in patients with type 2 diabetes mellitus: mediating effect of blood pressure.

Wang X, Huang X, Xing Y, Jiang X, Hua F Front Endocrinol (Lausanne). 2025; 16:1510737.

PMID: 40013309 PMC: 11860091. DOI: 10.3389/fendo.2025.1510737.

The comorbidity burden of diabetes and stroke: a retrospective study in Beijing, China.

Huang L, Zeng J, Luo Y, Wang H, Zhang Z, Zeng Y BMC Public Health. 2025; 25(1):546.

PMID: 39930417 PMC: 11812224. DOI: 10.1186/s12889-025-21705-8.

Impact of hypertension on changes in peripapillary retinal nerve fiber layer thickness in type 2 diabetes patients.

Sung J, Kang T, Lee K, Lee M Sci Rep. 2025; 15(1):792.

PMID: 39755783 PMC: 11700097. DOI: 10.1038/s41598-025-85295-6.

6. Glycemic Goals and Hypoglycemia: Standards of Care in Diabetes-2025.

Diabetes Care. 2024; 48(Supplement_1):S128-S145.

PMID: 39651981 PMC: 11635034. DOI: 10.2337/dc25-S006.

The effect of HbA1c variability on the efficacy of intensive blood pressure control in patients with type 2 diabetes.

Wang X, Pei J, Zheng K, Liu M, Hu X Diabetes Obes Metab. 2024; 27(3):1208-1216.

PMID: 39628286 PMC: 11802401. DOI: 10.1111/dom.16112.

References

. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. UK Prospective Diabetes Study Group. BMJ. 1998; 317(7160):703-13. PMC: 28659. View

Wei M, Gaskill S, Haffner S, Stern M . Effects of diabetes and level of glycemia on all-cause and cardiovascular mortality. The San Antonio Heart Study. Diabetes Care. 1998; 21(7):1167-72. DOI: 10.2337/diacare.21.7.1167. View

. Cost effectiveness analysis of improved blood pressure control in hypertensive patients with type 2 diabetes: UKPDS 40. UK Prospective Diabetes Study Group. BMJ. 1998; 317(7160):720-6. PMC: 28661. View

Borghi C, Ambrosioni E . Evidence-based medicine and ACE inhibition. J Cardiovasc Pharmacol. 1998; 32 Suppl 2:S24-35. DOI: 10.1097/00005344-199800004-00005. View

. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group. Lancet. 1998; 352(9131):837-53. View

Ferrari R . Effect of ACE inhibition on myocardial ischaemia. Eur Heart J. 1998; 19 Suppl J:J30-5. View

Meltzer S, LEITER L, Daneman D, Gerstein H, Lau D, Ludwig S . 1998 clinical practice guidelines for the management of diabetes in Canada. Canadian Diabetes Association. CMAJ. 1998; 159 Suppl 8:S1-29. PMC: 1255890. View

Svetkey L, Vollmer W, Appel L, Conlin P, Ryan D, Ard J . Effects of dietary patterns on blood pressure: subgroup analysis of the Dietary Approaches to Stop Hypertension (DASH) randomized clinical trial. Arch Intern Med. 1999; 159(3):285-93. DOI: 10.1001/archinte.159.3.285. View

Tuomilehto J, Rastenyte D, Birkenhager W, Thijs L, Antikainen R, Bulpitt C . Effects of calcium-channel blockade in older patients with diabetes and systolic hypertension. Systolic Hypertension in Europe Trial Investigators. N Engl J Med. 1999; 340(9):677-84. DOI: 10.1056/NEJM199903043400902. View

10.

Bruno G, Merletti F, Boffetta P, Cavallo-Perin P, Bargero G, Gallone G . Impact of glycaemic control, hypertension and insulin treatment on general and cause-specific mortality: an Italian population-based cohort of type II (non-insulin-dependent) diabetes mellitus. Diabetologia. 1999; 42(3):297-301. DOI: 10.1007/s001250051154. View

11.

. Joint British recommendations on prevention of coronary heart disease in clinical practice. British Cardiac Society, British Hyperlipidaemia Association, British Hypertension Society, endorsed by the British Diabetic Association. Heart. 1999; 80 Suppl 2:S1-29. PMC: 1766497. View

12.

Freemantle N, Cleland J, Young P, Mason J, Harrison J . beta Blockade after myocardial infarction: systematic review and meta regression analysis. BMJ. 1999; 318(7200):1730-7. PMC: 31101. DOI: 10.1136/bmj.318.7200.1730. View

13.

Eriksson J, Lindstrom J, Valle T, Aunola S, Hamalainen H, Ilanne-Parikka P . Prevention of Type II diabetes in subjects with impaired glucose tolerance: the Diabetes Prevention Study (DPS) in Finland. Study design and 1-year interim report on the feasibility of the lifestyle intervention programme. Diabetologia. 1999; 42(7):793-801. DOI: 10.1007/s001250051229. View

14.

. Efficacy of atenolol and captopril in reducing risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 39. UK Prospective Diabetes Study Group. BMJ. 1998; 317(7160):713-20. PMC: 28660. View

15.

Hansson L, Zanchetti A, Carruthers S, Dahlof B, Elmfeldt D, Julius S . Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. HOT Study Group. Lancet. 1998; 351(9118):1755-62. DOI: 10.1016/s0140-6736(98)04311-6. View

16.

. The sixth report of the Joint National Committee on prevention, detection, evaluation, and treatment of high blood pressure. Arch Intern Med. 1997; 157(21):2413-46. DOI: 10.1001/archinte.157.21.2413. View

17.

Van den Hoogen P, Feskens E, Nagelkerke N, Menotti A, Nissinen A, Kromhout D . The relation between blood pressure and mortality due to coronary heart disease among men in different parts of the world. Seven Countries Study Research Group. N Engl J Med. 2000; 342(1):1-8. DOI: 10.1056/NEJM200001063420101. View

18.

Yusuf S, Sleight P, Pogue J, Bosch J, Davies R, Dagenais G . Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. N Engl J Med. 2000; 342(3):145-53. DOI: 10.1056/NEJM200001203420301. View

19.

. Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy. Heart Outcomes Prevention Evaluation Study Investigators. Lancet. 2000; 355(9200):253-9. View

20.

Stratton I, Adler A, Neil H, Matthews D, Manley S, Cull C . Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ. 2000; 321(7258):405-12. PMC: 27454. DOI: 10.1136/bmj.321.7258.405. View